Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 anal carcinoma?
✍ Scribed by L. Moureau-Zabotto; F. Viret; M. Giovaninni; B. Lelong; E. Bories; J.R. Delpero; C. Pesenti; F. Caillol; C. de Chaisemartin; M. Minsat; G. Monges; A. Sarran; M. Resbeut
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 234 KB
- Volume
- 104
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background
This study retrospectively describes the outcome of a series of 38 patients (pts) with T4 anal carcinoma exclusively treated by radio and chemotherapy.
Patients and Methods
From 1992 to 2007, 38 pts with UST4‐N0‐2‐M0 anal carcinoma were treated with exclusive radiotherapy and chemotherapy. All patients received external beam radiotherapy (EBRT) (median dose 45 Gy) with a concomitant chemotherapy (5‐fluorouracil‐cisplatin). Eleven patients received neo‐adjuvant chemotherapy (5‐fluorouracil‐cisplatin). After 2–8 weeks, a 15–20 Gy boost was delivered either with EBRT (20 pts) or interstitial ^192^Ir brachytherapy (18 pts). Mean follow‐up was 66 months.
Results
After chemoradiation therapy (CRT), 13 pts (34%) had a complete response, 23 pts (60%) a response >50% (2 pts were not evaluated). The 5‐year‐disease‐free survival was 79.2 ± 6.5%, and the 5‐year overall survival was 83.9 ± 6%. Eight patients developed tumor progression (mean delay 8.8 months), six of them requiring a salvage surgery with definitive colostomy for local relapse. Late severe complication requiring colostomy was observed in 2 pts. The 5‐year‐colostomy‐free survival was 78 ± 6.9%. Patients who received primary chemotherapy had a statistically significant better 5‐year colostomy‐free survival (100% vs. 38 ± 16.4%, P = 0.0006).
Conclusion
T4 anal carcinoma can be treated with a curative intent using a sphincter‐sparing approach of CRT, and neo‐adjuvant chemotherapy should be considered prior to radiotherapy. J. Surg. Oncol. 2011;104:66–71. © 2011 Wiley‐Liss, Inc.